## Amendments to the Claims

1. (Currently Amended) A compound having a structural Formula I,

$$Z - (CH_2)_m - S - N - [C]_n - R^{1a}$$

$$Q - R^{1} - R^{1b} - R^{2a}$$

<u>or and pharmaceutically acceptable salts, solvates, hydrates</u> or stereoisomers thereof, wherein:

A is: 
$$P \longrightarrow Q$$
 or  $P \longrightarrow E$   $P \longrightarrow R^3$ ,  $P \longrightarrow R^4$   $P \longrightarrow R^5$   $P \longrightarrow R^3$ ,  $P \longrightarrow R^4$   $P \longrightarrow R^5$ 

E is selected from the group consisting of: O, S and or NR<sup>14</sup>;

W is selected from the group consisting of:

(CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub>

(cycloalkyl, haloalkyl and or acyl;

Q is:  $-C(O)OR^6$  or  $R^{6A}$ ;

X is selected from the group consisting of: a bond,  $CH_2$ , O, S and G S[O]<sub>p</sub>;

Y is selected from the group consisting of: a bond, S, CH<sub>2</sub> and or O;

Z is: <u>benzothiophene</u>: a) aliphatic group,

- b) aryl,
  - e) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
  - d) bi aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,

bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and heterocyclyl; wherein the benzothiophenealiphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl-and heterocyclyl being is optionally substituted with one or more groups independently selected from R<sup>15</sup>; m and n' are each independently selected from the group consisting of: 0, 1, 2, 3 and or 4; n is selected from the group consisting of: 0, 1, 2 and or 3; p is: 1 or 2; r is selected from the group consisting of: 1, 2, 3 and or 4; v is: 1 or 2; R<sup>1</sup> is selected from the group consisting of: hydrogen, wherein when Z is phenyl or naphthyl and R2 is H, R1 is not H, haloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl,  $C_1$ - $C_6$  alkyl- $C_1$ - $C_6$  alkoxy, C<sub>1</sub>-C<sub>6</sub> alkyl-aryl, C2-C6 alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, (CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl,  $C_1$ - $C_6$  alkoxy, aryl, ander R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring; and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R<sup>15</sup>; R<sup>1a</sup> and R<sup>1b</sup> are each independently selected from the group consisting of: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, and or

R<sup>1</sup> and R<sup>1a</sup>, R<sup>1</sup> and R<sup>1b</sup>, R<sup>2</sup> and R<sup>1a</sup>, R<sup>2</sup> and R<sup>1b</sup> or R<sup>1a</sup> and R<sup>1b</sup> together being a 3- to 6-membered heterocyclyl or carbocyclyl ring whereinwhere at least one of R<sup>1a</sup> and R<sup>1b</sup> is not hydrogen;

## R<sup>2</sup> is selected from the group consisting of -hydrogen,

haloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl-C<sub>1</sub>-C<sub>6</sub> alkoxy,

C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,

C2-C6 alkenyl,

C2-C6 alkynyl,

(CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl,

 $C_1$ - $C_6$  alkoxy,

aryl, ander

R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring;, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

R<sup>2a</sup> is selected from the group consisting of: hydrogen, halo, or C<sub>1</sub>-C<sub>6</sub> alkyl and wherein R<sup>2</sup> and R<sup>2a</sup> together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

## R<sup>3</sup> is selected from the group consisting of: hydrogen,

halo,

cyano,

haloalkyl,

 $C_1$ – $C_6$  alkyl,

(CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl,

(C<sub>1</sub>–C<sub>4</sub> alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with  $\frac{1}{0}$  oxo,  $\frac{1}{0}$  and

 $(C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9$ : and

wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

```
R<sup>4</sup> and R<sup>5</sup> are each independently selected from the group consisting of:

hydrogen,
halo,

C<sub>1</sub>-C<sub>6</sub> alkyl

C<sub>1</sub>-C<sub>6</sub> alkoxy;
aryloxy;
N(R<sup>8</sup>)<sub>2</sub>,
SR<sup>8</sup> and \(\text{and}\) \(\text{R}^5\) together being a 3- to 8-membered ring;

R<sup>6</sup> is selected from the group consisting of: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl and \(\text{er}\) aminoalkyl;

R<sup>6A</sup> is selected from the group consisting of: carboxamide, C<sub>1</sub>-C<sub>3</sub> alkylnitrile, sulfonamide, acylsulfonamide and \(\text{er}\) tetrazole;

R<sup>7</sup> is selected from the group consisting of: -hydrogen and \(\text{er}\) C<sub>1</sub>-C<sub>6</sub> alkyl;
```

- R<sup>8</sup> and R<sup>9</sup> are each independently selected from the group consisting of:
  hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl, and or heterocyclyl;, and
  wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more
  substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo,
  haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy;
- R<sup>14</sup> is selected from the group consisting of: hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub> alkyl, and or C<sub>1</sub>-C<sub>6</sub> alkyl-COOR<sup>6</sup>, and wherein aryl and alkyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>; and
- R<sup>15</sup> is selected from the group consisting of: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, (CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl, N(R<sup>8</sup>)<sub>2</sub>, NR<sup>8</sup>S(O)<sub>2</sub>R<sup>9</sup>, NR<sup>8</sup>C(O)<sub>p</sub>R<sup>9</sup>, C(O)NR<sup>8</sup>R<sup>9</sup>, C(O)<sub>p</sub>R<sup>8</sup>, SR<sup>8</sup>, S(O)<sub>p</sub>R<sup>8</sup> and or S(O)<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>.

Serial No.: 10/542579

Docket No.: X-16180

2. (Currently Amended) The compound Claim 1, wherein X and Y are respectively S and O; S and  $C\underline{H}_2$ ; or  $C\underline{H}_2$  and O.

- 3. (Canceled)
- 4. (Canceled)
- 5. (Currently Amended) The compound of Claim 1 Claim 4, wherein  $R^1$  is  $C_3$ - $C_6$  alkyl or  $(CH_2)_n \cdot C_3 \cdot C_6$  cycloalkyl;  $R^2$  and  $R^3$  are each independently  $C_1 \cdot C_3$  alkyl; and r is 1.
- 6. (Original) The compound Claim 5, wherein X is positioned para to Y; and R<sup>3</sup> is positioned ortho to Y.
  - 7. (Currently Amended) A compound having a structural Formula II,

$$Z - (CH_2)_m - S - N - [C]_n - [C]_n - [R^{1a}]_{R^{1b}} - [R^{2a}]_{r}$$

<u>orand</u> pharmaceutically acceptable salts<del>, solvates, hydrates</del> or stereoisomers thereof, wherein:

Q is:  $-C(O)OR^6$  or  $R^{6A}$ ;

 $X \text{ is } \underline{\text{selected from the group consisting of}} \quad \text{a bond, } C\underline{H_2}, O, S \underline{\text{and}} \underline{\text{or}} S[O]_p;$ 

Y is selected from the group consisting of: a bond, S, CH<sub>2</sub> and or O;

Z is benzothiopene:

a) — aliphatic group.

b) — aryl,

e) — a 5 to 10 membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,

d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl.

e) bi heteroaryl, wherein bi heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and

heterocyclyl;

wherein the benzothiophenealiphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heteroeyelyl being-is optionally substituted with one or more groups independently selected from R<sup>15</sup>;

1, 2, 3 and or 4;

m and n' are each independently selected from the group consisting of: 0, 1, 2, 3 and or 4; n is selected from the group consisting of: 0, 1, 2 and or 3; p is: 1 or 2;

R<sup>1</sup> is selected from the group consisting of: aryl,

haloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl,

 $C_1$ - $C_6$  alkyl- $C_1$ - $C_6$  alkoxy,

r is selected from the group consisting of:

C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,

C2-C6 alkenyl,

C2-C6 alkynyl,

(CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl,

C1-C6 alkoxy and or

R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring;, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

R<sup>1a</sup> and R<sup>1b</sup> are each independently selected from the group consisting of hydrogen,

C<sub>1</sub>-C<sub>6</sub> alkyl, and, or

R<sup>1</sup> and R<sup>1a</sup>, R<sup>1</sup> and R<sup>1b</sup>, R<sup>2</sup> and R<sup>1a</sup>, R<sup>2</sup> and R<sup>1b</sup> or or R<sup>1a</sup> and R<sup>1b</sup> together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R<sup>1a</sup> and R<sup>1b</sup> is not hydrogen;

```
R<sup>2</sup> is selected from the group consisting of: hydrogen,
         haloalkyl,
         C<sub>1</sub>-C<sub>6</sub> alkyl,
       C_1-C_6 alkyl-C_1-C_6 alkoxy,
         C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
         C2-C6 alkenyl,
         C2-C6 alkynyl,
         (CH<sub>2</sub>)<sub>n</sub>,C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
         C<sub>1</sub>-C<sub>6</sub> alkoxy,
         aryl, ander
         R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring;, and
         wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted
         with one or more groups independently selected from R<sup>15</sup>;
R<sup>2a</sup> is selected from the group consisting of hydrogen, halo, or C<sub>1</sub>-C<sub>6</sub> alkyl, and wherein R<sup>2</sup>
         and R<sup>2a</sup> together being a 3- to 8-membered ring;-and-wherein alkyl being optionally
         substituted with one or more groups independently selected from R<sup>15</sup>;
R<sup>3</sup> is selected from the group consisting of hydrogen,
         halo,
         cyano,
         haloalkyl,
         C_1-C_6 alkyl,
         (CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
          (C<sub>1</sub>-C<sub>4</sub> alkyl)-heterocyclyl, and wherein the heterocyclyl being optionally substituted with
                   oxo.
         (C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9; and
         wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more
         groups independently selected from R<sup>15</sup>;
R<sup>4</sup> and R<sup>5</sup> are each independently selected from the group consisting of:
```

hydrogen,

halo,

C<sub>1</sub>-C<sub>6</sub> alkyl

 $C_1$ - $C_6$  alkoxy;

aryloxy;

 $N(R^8)_2$ ,

SR8 ander

R<sup>4</sup> and R<sup>5</sup> together being a 3- to 8-membered ring;

R<sup>6</sup> is selected from the group consisting of: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl and or aminoalkyl;

 $R^{6A}$  is selected from the group consisting of: carboxamide,  $C_1$ - $C_3$  alkylnitrile, sulfonamide, acylsulfonamide and or tetrazole;

R<sup>7</sup> is selected from the group consisting of: hydrogen and or C<sub>1</sub>-C<sub>6</sub> alkyl;

- $R^8$  and  $R^9$  are each independently selected from the group consisting of: hydrogen,  $C_1$ - $C_6$  alkyl, aryl, heteroaryl, and or heterocyclyl; and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo,  $C_1$ - $C_6$  alkyl and  $C_1$ - $C_6$  alkoxy;
- R<sup>15</sup> is selected from the group consisting of: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, (CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl, N(R<sup>8</sup>)<sub>2</sub>, NR<sup>8</sup>S(O)<sub>2</sub>R<sup>9</sup>, NR<sup>8</sup>C(O)<sub>p</sub>R<sup>9</sup>, C(O)NR<sup>8</sup>R<sup>9</sup>, C(O)<sub>p</sub>R<sup>8</sup>, SR<sup>8</sup>, S(O)<sub>p</sub>R<sup>8</sup> and or S(O)<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>.
- 8. (Currently Amended) The compound of Claim 7, wherein X and Y are respectively S and O; S and  $C\underline{H_2}$ ; or  $C\underline{H_2}$  and O.
  - 9. (Canceled)
  - 10. (Canceled)
- (Currently Amended) The compound of Claim 8 Claim 10, wherein  $R^1$  is  $C_3$ - $C_6$  alkyl or  $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl;  $R^2$  and  $R^3$  are each independently  $C_1$ - $C_3$  alkyl; and r is 1.

12. (Original) The compound Claim 11, wherein X is positioned para to Y; and  $R^3$  is positioned ortho to Y.

13. (Currently Amended) The compound of Claim 7, wherein the compound having a structural Formula III,

orand pharmaceutically acceptable salts-solvates, hydrates or or stereoisomers thereof, wherein:

n is: 1 or 2;

r is: 1, 2, 3, or 4;

X is: S or CH2;

Y is:  $CH_2$  or O;

Z is: aryl or a 5- to 10-membered heteroaryl, benzothiophene;

wherein aryl and heteroaryl beingthe benzothiophene is optionally substituted with one or more groups independently selected from R<sup>15</sup>;

 $R^1$  and  $R^2$  are each independently selected from the group consisting of:  $C_1$ - $C_6$  alkyl and  $C_1$ - $C_6$  cycloalkyl; and

 $R^{1a}$  and  $R^{1b}$ ,  $R^3$ ,  $R^4$  and  $R^5$  are each independently selected from the group consisting of hydrogen and  $C_1$ - $C_6$  alkyl.

- 14. (Canceled)
  - 15. (Canceled)
    - 16. (Cancelled)
    - 17. (Currently Amended) A compound having a structural Formula VI,

Serial No.: 10/542579

Docket No.: X-16180

$$Z \xrightarrow{\begin{array}{c} O \\ = \\ N \end{array}} \begin{bmatrix} R^{1a} \\ = \\ N \end{array} \xrightarrow{\begin{array}{c} (R^3)_r \\ = \\ N \end{array}} \begin{bmatrix} C \\ R^{1b} \\ R^{2a} \end{bmatrix} VI$$

<u>orand</u> pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein: X is selected from the group consisting of: a bond,  $CH_2$ , O, S and SG(O),

Y is selected from the group consisting of:

a bond, S, CH2 and or O;

Z is <u>benzothiophene</u>; heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S, and wherein heteroaryl being optionally the benzotihophene is <u>optionally</u> substituted with one or more groups selected from R<sup>15</sup>;

n is: 0, 1, 2 or 3;

n' is: 0, 1, 2, 3 or 4;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

 $R^1$  is selected from the group consisting of  $\leftarrow$  hydrogen,

haloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl,

 $C_1$ - $C_6$  alkyl- $C_1$ - $C_6$  alkoxy,

C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,

C2-C6 alkenyl,

C2-C6 alkynyl,

(CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkoxy,

aryl, ander

R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring;, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

```
R<sup>1a</sup> and R<sup>1b</sup> are each independently selected from the group consisting of:
           hydrogen,
           C<sub>1</sub>-C<sub>6</sub> alkyl, ander
           R<sup>1</sup> and R<sup>1a</sup>, R<sup>1</sup> and R<sup>1b</sup>, R<sup>2</sup> and R<sup>1a</sup>, R<sup>2</sup> and R<sup>1b</sup> or R<sup>1a</sup> and R<sup>1b</sup> together being a 3- to 6-
           membered heterocyclyl or carbocyclyl ring; wherein where at least one of R<sup>1a</sup> and R<sup>1b</sup> is
           not hydrogen;
R<sup>2</sup> is selected from the group consisting of: hydrogen,
           haloalkyl,
           C<sub>1</sub>-C<sub>6</sub> alkyl,
           C<sub>1</sub>-C<sub>6</sub> alkyl-C<sub>1</sub>-C<sub>6</sub> alkoxy,
           C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
           C2-C6 alkenyl,
           C<sub>2</sub>-C<sub>6</sub> alkynyl,
           (CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
           C<sub>1</sub>-C<sub>6</sub> alkoxy,
           aryl, ander
           R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring; and
           wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted
           with one or more groups independently selected from R<sup>15</sup>;
R<sup>2a</sup> is selected from the group consisting of: hydrogen, halo and or C<sub>1</sub>-C<sub>6</sub> alkyl: and wherein R<sup>2</sup>
           and R<sup>2a</sup> together being a 3- to 8-membered ring;-and wherein alkyl being optionally
           substituted with one or more groups independently selected from R<sup>15</sup>;
R<sup>3</sup> is selected from the group consisting of: hydrogen,
           halo,
           cyano,
           haloalkyl,
           C<sub>1</sub>-C<sub>6</sub> alkyl,
           (CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
```

(C<sub>1</sub>-C<sub>4</sub> alkyl)-heterocyclyl, and wherein the heterocyclyl being optionally substituted with exe.

 $(C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9,:-\text{and}$ 

wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

R<sup>6</sup> is selected from the group consisting of: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl and or aminoalkyl;

R<sup>7</sup> is selected from the group consisting of: hydrogen and or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>8</sup> and R<sup>9</sup> are each independently selected from the group consisting of:
hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl, ander heterocyclyl; and
wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more
substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo,
haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy; and

R<sup>15</sup> is selected from the group consisting of: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, N(R<sup>8</sup>)<sub>2</sub>, NR<sup>8</sup>S(O)<sub>2</sub>R<sup>9</sup>, NR<sup>8</sup>C(O)<sub>p</sub>R<sup>9</sup>, C(O)<sub>p</sub>R<sup>8</sup>, SR<sup>8</sup>, S(O)<sub>p</sub>R<sup>8</sup> and or S(O)<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>.

18. (Currently Amended) The compound of Claim17, wherein the compound having a structural Formula VII,

$$(R^{10})_{q} \xrightarrow{\begin{array}{c} 4 \\ 6 \end{array} } \xrightarrow{\begin{array}{c} 7 \\ 7 \end{array}} \xrightarrow{\begin{array}{c} 1 \\ 7 \end{array}$$

<u>orand</u> pharmaceutically acceptable salts <u>or</u>, <u>solvates</u>, <u>hydrates or</u> stereoisomers thereof, wherein:

q is: 1, 2, 3, or 4;

T isis: O, NR to or S;

R<sup>1e</sup> is: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>10</sup> and R<sup>11</sup> are each independently<u>selected from the group consisting of</u>-

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy,

C<sub>1</sub>-C<sub>6</sub> alkyl and or C<sub>1</sub>-C<sub>6</sub> alkoxy; and

wherein alkyl, aryloxy, and alkoxy being optionally substituted with one or more groups independently selected from R<sup>15</sup>.

19. (Currently Amended) The compound of Claim 18, wherein the compound having a structural Formula VIII,

$$(R^{10})_{q} \xrightarrow{\begin{array}{c} 4 \\ 5 \\ 6 \end{array}} \xrightarrow{\begin{array}{c} 7 \\ 7 \end{array}} \xrightarrow{\begin{array}{c} 11 \\ 5 \\ 0 \end{array}} \xrightarrow{\begin{array}{c} 11 \\ 7 \\ 0 \end{array}} \xrightarrow{\begin{array}{c} 11 \\ 11 \\ 0 \end{array}} \xrightarrow{\begin{array}{c} 11 \\ R^{2} \end{array}} \xrightarrow{\begin{array}{c} 11 \\ R^{2} \end{array}} \xrightarrow{\begin{array}{c} 11 \\ 11 \\ 0 \end{array}} \xrightarrow{\begin{array}{c} 11 \\ 11 \\ 11 \end{array}} \xrightarrow{\begin{array}{c} 11 \\ 11 \\ 11 \end{array}} \xrightarrow{\begin{array}{c} 11 \\$$

<u>orand</u> pharmaceutically acceptable salts. solvates, hydrates or stereoisomers thereof, wherein:

q is: 1 or 2;

 $R^1$  is selected from the group consisting of:  $C_3$ - $C_5$  alky and  $C_3$ - $C_6$  cycloalkyl;

R<sup>2</sup> and R<sup>3</sup> are each independently: C<sub>1</sub>-C<sub>3</sub> alkyl;

R<sup>10</sup> is selected from the group consisting of ÷halo, haloalkyl and or C<sub>1</sub>-C<sub>3</sub> alkyl: and wherein R<sup>10</sup> being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring; and

 $R^{11}$  is selected from the group consisting of- hydrogen and  $C_1$ - $C_6$  alkyl.

- 20. (Original) The compound of Claim 19, wherein R<sup>10</sup> is Cl, F, Br, CH<sub>3</sub> or CF<sub>3</sub> being substituted at a position 5 of benzothiophenyl ring.
  - 21. (Currently Amended) A compound having a structural Formula IX,

$$Z - (CH_2)_m - S - N - [C]_n - R^{1a} - R^{2a} - (R^3)_r$$

$$IX$$

<u>orand</u> pharmaceutically acceptable salts<del>, solvates, hydrates</del> or stereoisomers thereof, wherein: E is <u>selected from the group consisting of</u>: O, S <u>andor NR</u><sup>14</sup>;

W is selected from the group consisting of: cycloalkyl, haloalkyl and or acyl;

Q is selected from the group consisting of: -C(O)OR<sup>6</sup> and or R<sup>6A</sup>;

X is selected from the group consisting of: a bond, C, O, S and or S[O]p;

Y is selected from the group consisting of: a bond, S, CH<sub>2</sub> or and O;

Z is benzothiopene: and: a) aliphatic group.

- b) arvl
- e) a 5-to-10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S.
  - d) bi aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,
  - e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and
  - f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi aryl, bi heteroaryl and heterocyclyl beingthe benzothiophene is optionally substituted with one or more groups independently selected from R<sup>15</sup>;

m and n' are each independently: 0, 1, 2, 3 or 4;

```
n is:
           0, 1, 2 or 3;
p is:
           1 or 2;
           1, 2, 3 or 4;
r is:
v is:
           1 or 2;
R<sup>1</sup> is selected from the group consisting of: hydrogen,
           haloalkyl,
           C<sub>1</sub>-C<sub>6</sub> alkyl,
           C_1-C_6 alkyl-C_1-C_6 alkoxy,
           C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
           C2-C6 alkenyl,
           C<sub>2</sub>-C<sub>6</sub> alkynyl,
           (CH<sub>2</sub>)<sub>n'</sub>C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
           C<sub>1</sub>-C<sub>6</sub> alkoxy,
           aryl, ander
           R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring; and
           wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted
           with one or more groups independently selected from R<sup>15</sup>;
R<sup>1a</sup> and R<sup>1b</sup> are each independently selected from the group consisting of
           hydrogen,
           C<sub>1</sub>-C<sub>6</sub> alkyl, ander
           R<sup>1</sup> and R<sup>1a</sup>, R<sup>1</sup> and R<sup>1b</sup>, R<sup>2</sup> and R<sup>1a</sup>, R<sup>2</sup> and R<sup>1b</sup> or R<sup>1a</sup> and R<sup>1b</sup> together being a 3- to 6-
           membered heterocyclyl or carbocyclyl ring whereinwhere at least one of R<sup>1a</sup> and R<sup>1b</sup> is not
           hydrogen;
R<sup>2</sup> is selected from the group consisting of: hydrogen,
           haloalkyl,
           C<sub>1</sub>-C<sub>6</sub> alkyl,
           C<sub>1</sub>-C<sub>6</sub> alkyl-C<sub>1</sub>-C<sub>6</sub> alkoxy,
           C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
           C2-C6 alkenyl,
           C2-C6 alkynyl,
```

Docket No.: X-16180

Serial No.: 10/542579

Docket No.: X-16180 Serial No.: 10/542579 (CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, aryl, ander R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring;, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R<sup>15</sup>; R<sup>2a</sup> is selected from the group consisting of: hydrogen, halo, or C<sub>1</sub>-C<sub>6</sub> alkyl and wherein R<sup>2</sup> and R<sup>2a</sup> together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>: R<sup>3</sup> is selected from the group consisting of: hydrogen, halo, cyano, haloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl, (CH<sub>2</sub>)<sub>n</sub>,C<sub>3</sub>-C<sub>6</sub> cycloalkyl, (C<sub>1</sub>-C<sub>4</sub> alkyl)-heterocyclyl,-wherein the heterocyclyl being optionally substituted with oxo, and  $(C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9$ : and wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>; R<sup>4</sup> and R<sup>5</sup> are each independently selected from the group consisting of: hydrogen, halo, C<sub>1</sub>-C<sub>6</sub> alkyl C<sub>1</sub>-C<sub>6</sub> alkoxy; aryloxy;

R<sup>6</sup> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl and or aminoalkyl;

R<sup>4</sup> and R<sup>5</sup> together being a 3- to 8-membered ring;

N(R<sup>8</sup>)<sub>2</sub>, SR<sup>8</sup> and<del>or</del>

R<sup>6A</sup> is selected from the group consisting of:———carboxamide, C<sub>1</sub>-C<sub>3</sub> alkylnitrile, sulfonamide, acylsulfonamide and er tetrazole;

R<sup>7</sup> is selected from the group consisting of: hydrogen and or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>8</sup> and R<sup>9</sup> are each independently selected from the group consisting of:
hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl, ander heterocyclyl; and
wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more
substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo,
haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy;

 $R^{14}$  is selected from the group consisting of: hydrogen, aryl,  $C_1$ - $C_6$  alkyl, and  $C_1$ - $C_6$  alkyl- $C_6$ 

wherein aryl and alkyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>; and

 $R^{15} \text{ is } \underline{\text{selected from the group consisting of}} \text{ hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl,} \\ \text{ haloalkyloxy, aryloxy, oxo, } C_1\text{-}C_6 \text{ alkyl, } C_1\text{-}C_6 \text{ alkoxy, } (CH_2)_n\text{-}C_3\text{-}C_6 \text{ cycloalkyl, } N(R^8)_2, \\ NR^8S(O)_2R^9, NR^8C(O)_pR^9, C(O)NR^8R^9, C(O)_pR^8, SR^8, S(O)_pR^8 \underline{\text{ander}} S(O)_2NR^8R^9.$ 

22. (Currently Amended) The compound of Claim 21, wherein the compound having a structural Formula X:

$$(R^{10})_q \xrightarrow{\begin{array}{c} 4 \\ 6 \end{array}} \xrightarrow{\begin{array}{c} 7 \\ 7 \end{array}} \xrightarrow{\begin{array}{c} R^{1a} \\ 1 \\ N \end{array}} \xrightarrow{\begin{array}{c} R^{1a} \\ 1 \\ N \end{array}} \xrightarrow{\begin{array}{c} R^{1a} \\ R^{1b} \end{array}} \xrightarrow{\begin{array}{c} Y \\ R^{2} \end{array}} \xrightarrow{\begin{array}{c} COOR^6 \\ R^4 \end{array}}$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

n and q are each independently: 1, 2, 3 or 4;

T is: O. NR to or S;

X is selected from the group consisting of: CH<sub>2</sub>, O and or S;

 $R^1$  is selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl and  $C_6$  (CH<sub>2</sub>)<sub>n</sub>· $C_3$ - $C_6$  cycloalkyl;  $R^{1a}$ ,  $R^{1b}$ ,  $R^{1c}$  and  $R^2$  are each independently selected from the group consisting of hydrogen and  $C_1$ - $C_6$  alkyl; and

R<sup>10</sup> and R<sup>11</sup> are each independently selected from the group consisting of:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy,

 $C_1$ - $C_6$  alkyl and  $C_1$ - $C_6$  alkoxy; and wherein alkyl, alkoxy and aryloxy being optionally substituted with one or more groups selected from  $R^{15}$ .

23. (Currently Amended) The compound of Claim 22, wherein the compound having a structural Formula XI:

$$(R^{10})_{q} \xrightarrow{5}_{6} \xrightarrow{7}_{7} \xrightarrow{S}_{0} \xrightarrow{R^{1}}_{R^{1}} \xrightarrow{R^{2}}_{R^{2}}$$

$$XI$$

<u>orand</u> pharmaceutically acceptable salts, <u>solvates</u>, <u>hydrates</u> or stereoisomers thereof, wherein: q is 1 or 2;

E is selected from the group consisting of O, S and or NR<sup>14</sup>;

 $R^1$ ,  $R^2$  and  $R^{11}$  are each independently selected from the group consisting of:  $C_1$ - $C_4$  alkyl;

R<sup>10</sup> is selected from the group consisting of: Cl, F, Br, CH<sub>3</sub> and or CF<sub>3</sub>; and wherein R<sup>10</sup> being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring; and

 $R^{14}$  is selected from the group consisting of hydrogen,  $C_1$ - $C_6$  alkyl and or aryl.

24. (Currently Amended) A compound selected from the group consisting of No. 1-120 and 121:

No.	Structure	Name
1	S S N S OH	3-(4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenyl)-propionic acid

No.	Structure	Name
2	CI OH	3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
3	CI OH	(4-{2-[(5-Chloro-3-methyl-benzofuran-2-sulfonyl) propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-acetic acid
4	CI OH	(4-{2-{(5-Chloro-3-methyl-benzofuran-2-sulfonyl)-propyl-amino}-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
5	CI S S N S	3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
	CI OH OH	(4-{2-[(5-Chloro-3-ethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

7	CI—OHOH	4-{2-[(6-Chloro-3-methyl-benzo[b]thiophene-2-
	s is in s	sulfonyl)-propyl-
	0 0	amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
8		4-{2-[(7-Chloro-3- methyl-
	OH OH	benzo[b]thiophene-2-
	cı s s N	sulfonyl)-propyl-
	ο΄ ὃ	amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
9	CI Q	(4-{2-[(4-Chloro-3-
		methyl- benzo[b]thiophene-2-
		sulfonyl)-propyl-
	s s v	amino]-ethylsulfanyl}-
	0	2-methyl-phenoxy)-
		acetic acid
10	CI FFI I O	(4-{2-[(5-Chloro-3-
	F O L	trifluoromethyl-
	HO, CA, OH	benzo[b]thiophene-2- sulfonyl)-propyl-
	s s, s, w	amino]-ethylsulfanyl}-
	0 0	2-methyl-phenoxy)-
		acetic acid
11	CF <sub>3</sub>	(4-{2-[(5-Chloro-3-
	S-N.	trifluoromethyl-
	s' " ) О О О О О О О О О О О О О О О О О О	benzo[b]thiophene-2-
	. (	sulfonyl)-propyl- amino]-1-methyl-
'		ethoxy}-2-methyl-
		phenoxy)-acetic acid
12	9	2-[4-(3-{[5-(4'-Fluoro
	ОУОН	biphenyl-4-yl)-
		thiophene 2-sulfonyl]
	0 0	propyl-amino)-propyl)-
		phenoxy] 2-methyl-
13	,	propionic acid 2-(4-{2-[(5-Chloro-3-
13	o < · ·	methyl-
	s Š.	benzo[b]thiophene-2-
		sulfonyl)-propyl-
		amino]-ethyl}-
	CI OH	phenoxy)-2-methyl-
	, , , , , , , , , , , , , , , , , , , ,	propionic acid

	,	1044055
14	OH OH	2-(4-{3-[(3,5-Dimethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-phenoxy)-2-methyl-propionic acid
15	F O N O O O O O O O O O O O O O O O O O	2-(4-{3-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-phenoxy)-2-methyl-propionic acid
16	O O O O O O O O O O O O O O O O O O O	2-(4-{3-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-(2,2,2-trifluoro-ethyl)-amino]-propyl}-phenoxy)-2-methyl-propionic acid
17	DESIGN OF THE PROPERTY OF THE	2-(4-{2-[(3-Ethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethoxy}-3-propyl-phenoxy)-2-methyl-propionic acid
18	CI S S O O O O O O O O O O O O O O O O O O	2-[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-2-methyl-propionic acid
19	CI S S S N	3-[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenyl]-propionic acid

20	F S O O O O O O O O O O O O O O O O O O O	[4-(1-{[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid
21	CI S O O O O O O O O O O O O O O O O O O	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid
22	CI C	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid
23	OH OH	(2 Methyl 4 {2 [(6- phenoxy-pyridine 3- sulfonyl)-propyl- amino] ethylsulfanyl} phenoxy)-acetic acid
24	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CO O O O O O O O O O O O O O O O O O O	(2 Methyl 4 {2 [(5-methyl 1 phenyl 1H-pyrazole 4 sulfonyl) propyl amino} ethylsulfanyl} phenoxy) acetic acid
25	CH <sub>3</sub>	(2 Methyl 4-{2-{(4-oxazol 5-yl-benzenesulfonyl)-propyl-amino}-ethylsulfanyl}-phenoxy) acetic acid
26	OH SHOW SHOW SHOW SHOW SHOW SHOW SHOW SH	(2 Methyl 4 {2 [propyl (1 pyrazol 1 yl benzenesulfonyl) amino] ethylsulfanyl} phenoxy) acetic acid

		<u> </u>
27	CH <sub>3</sub> CH <sub>3</sub> OH	(2 Methyl 4 {2 [(2-naphthalen 1 yl-ethanesulfonyl) propylamino] ethylsulfanyl}-phenoxy) acetic acid
28	F CH <sub>3</sub> CH <sub>3</sub>	(2-Methyl 4-{2-[propyl-(4-trifluoromethylphenylmethanesulfonyl) amino}ethylsulfanyl}-phenoxy) acetic acid
29	CH <sub>3</sub> CH <sub>3</sub>	(4-{2-{(Biphenyl-3-sulfonyl) propyl-amino] ethylsulfanyl}-2-methyl phenoxy) acetic acid
<del>30</del> .	CH <sub>3</sub>	(4-{2-[(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
31	H <sub>3</sub> C S N S CH <sub>3</sub>	[2-Methyl-4-(2-{[5-(2-methylsulfanyl-pyrimidin 4-yl)-thiophene 2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid
32	F N CH <sub>3</sub> OH	[2 Methyl 4 (2 {[5 (1-methyl 5-trifluoromethyl 111-pyrazol 3-yl) thiophene-2-sulfonyl] propylamino} ethylsulfanyl) phenoxy] acetic acid
<del>33</del>	E F CH <sub>3</sub> OH	[2 Methyl 4 (2 {[5 (1-methyl-3-trifluoromethyl-11-l-pyrazol 4-yl) thiophene-2-sulfonyl] propylamino}-othylsulfanyl)-phenoxy]-acetic acid
34	F CH <sub>3</sub> Chiral  S CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> OH  CH <sub>3</sub> OH	(R)-(2-Methyl-4-{1- methyl-2-[(3-methyl-5- trifluoromethyl- benzo[b]thiophene-2- sulfonyl)-propyl-

		amino]-ethylsulfanyl}-
		phenoxy)-acetic acid
35	CH <sub>3</sub> chiral	(R)-3-(4-{2-[(6-Chloro-
	F S CH <sub>3</sub>	5-fluoro-3-methyl-
	CI S O CH.	benzo[b]thiophene-2-
	CI CI CH <sub>3</sub>	sulfonyl)-propyl-
	LH3 OH	amino]-1-methyl-
	•	ethylsulfanyl}-2-
		methyl-phenyl)-
26	OU Airel	propionic acid
36	CH <sub>3</sub> chiral	(R)-(4-{2-[(6-Chloro-5-
	I S CH <sub>3</sub>	fluoro-3-methyl-
	CI CH <sub>3</sub> CH <sub>3</sub>	benzo[b]thiophene-2-
		sulfonyl)-propyl-
	сн₃ о́н	amino]-1-methyl-
		ethylsulfanyl}-2-
		methyl-phenoxy)-acetic acid
37	0	(4-{2-[(4-Bromo-
<del>37</del>	O II S CH <sub>3</sub>	benzenesulfonyl)
	N 2 N 2 N 2 N 2 N 2 N 2 N 2 N 2 N 2 N 2	propyl-amino]-
		ethylsulfanyl) 2-
	Br O	methyl-phenoxy) acetic
	ĊH₃ ÓH	acid
38	_ 0	(4-{2-[(3,4-Dichloro-
	O O O CH <sub>3</sub>	benzenesulfonyl)
		propyl-amino]
	CI	ethylsulfanyl} 2-
		methyl-phenoxy) acetic
	CH <sub>3</sub> OH	acid
39	0	(4-{2-[(4-Isopropyl-
	S CH <sub>3</sub>	benzenesulfonyl)-
		propyl-amino}-
	H <sub>3</sub> C	ethylsulfanyl} 2
	l сн, сн, он	methyl-phenoxy) acetic
		acid
40	O   CH	(2-Methyl-4-{2-[(4-
. *	S CH <sub>3</sub>	pentyl-
		benzenesulfonyl)
	H <sub>3</sub> C N	propyl-amino]
	CH₃ OH	ethylsulfanyl)
		phenoxy) acetic acid
41	CI O	(4-{2-[(2-Chloro-4-
	S CH <sub>3</sub>	trifluoromethyl-
		benzenesulfonyl)-
		propyl-amino]-
	I	ethylsulfanyl) 2
		methyl-phenoxy) acetic
		acid

42	F F O S N S CH <sub>3</sub>	(2 Methyl 4 {2 [propyl- (3 trifluoromethyl- benzenesulfonyl)- amino] ethylsulfanyl}- phenoxy) acetic acid
43	CH <sub>3</sub> O CH <sub>3</sub> CH <sub>3</sub>	(4-{2-{(4-Bromo-2-methyl-benzenesulfonyl)-propyl-amino}-ethylsulfanyl}-2-methyl-phenoxy) acetic acid
44	Br CH <sub>3</sub> CH <sub>3</sub>	(4-{2-[(3,4-Dibromo- benzenesulfonyl)- propyl-amino}- ethylsulfanyl}-2- methyl-phenoxy) acetic acid
4 <del>5</del>	H <sub>3</sub> C CH <sub>3</sub> OH	(2 Methyl 4 {2 [propyl- (4 propyl- benzenesulfonyl)- amino] ethylsulfanyl}- phenoxy) acetic acid
46	CI ON S CH3	(4-{2-[(2,4-Dichlorobenzenesulfonyl)-propyl-amino}ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
47	CH <sub>3</sub>	(4-{2-{(4-lodo-benzenesulfonyl)-propyl-amino}-ethylsulfanyl}-2-methyl-phenoxy) acetic acid

		1 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2 (2
48	CI S CH <sub>3</sub>	<del>(4-{2-[(3-Chloro-4-methyl-</del>
		benzenesulfonyl)-
	H³C O A	propyl-amino]-
	Ċн <sub>з</sub> он	ethylsulfanyl}-2-
	•	methyl-phenoxy) acetic
		acid
49	F 0	(4 {2 [(4 Bromo 2,5
		difluoro-
		<del>benzenesulfonyl)</del>
	Br O	propyl-amino]
		ethylsulfanyl}-2-
	Ė СН <sub>3</sub> ОН	methyl phenoxy) acetic
		acid
<del>50</del>	O chiral	(2-Methyl-4-{1-methyl-
		<del>2-[propyl-(4-</del>
		trifluoromethyl-
	F CH <sub>3</sub>	benzenesulfonyl)
		amino] ethylsulfanyl}-
	F CH₃ OH	phenoxy) acetic acid
51	chiral	(4-{2-[(3,4-Dichloro-
		benzenesulfonyl)
	CI S CH <sub>3</sub>	propyl-amino]-1-
	CH <sub>3</sub>	methyl-ethylsulfanyl}
	CI CH <sub>3</sub>	2-methyl-phenoxy)-
	CH <sub>3</sub> OH	acetic acid
52		
ਰ ਤੋਂ ±	0 0 	(2 Methyl 4 {2 [propyl- (2' trifluoromethyl-
	· \	
		biphenyl 4 sulfonyl)
		amino] ethylsulfanyl)
	Сн <sub>3</sub> Он	phenoxy) acetic acid
53	O S CH <sub>3</sub>	(2-Methyl-4-{2-[propyl-
	F E CH <sub>3</sub>	(3'-trifluoromethyl-
		biphenyl 4 sulfonyl)
		amino]-ethylsulfanyl}-
	ĊH₃ OH	phenoxy)-acetic acid
54	0=	(2 Methyl-4-{2-[propyl-
1	S CH <sub>3</sub>	(4'-trifluoromethyl-
		biphenyl-1-sulfonyl)
	F	amino] ethylsulfanyl}
	F CH₃ ÓH	phenoxy) acetic acid
	l F	F. Strong J. House Main
55	0 0 1	(4-{2-[(2' Fluoro-
	F S N S CH <sub>3</sub>	biphenyl-4-sulfonyl)
		propyl-amino]
		ethylsulfanyl) 2
	CH <sub>3</sub> OH	methyl-phenoxy)-acetic
	, v	acid
		·

	0	(4 (2 [(4) [2]
<del>56</del>	O II S S S CH <sub>3</sub>	(4 {2 [(4' Fluoro biphenyl 4 sulfonyl)
		propyl-amino]-
0		ethylsulfanyl) 2
	сн, он	methyl-phenoxy) acetic
	r	acid
<del>57</del>	0   0	(2-Methyl-4-{2-[propyl-
	S N S CH3	(4' trifluoromethoxy
ļ	F	biphenyl-4-sulfonyl)
	г сн₃ он	amino]-ethylsulfanyl}-
	j į į	phenoxy) acetic acid
<del>58</del>	O S CH.	(4-{2-[(3',4'-Dichloro-
		biphenyl 4 sulfonyl) propyl aminol
		ethylsulfanyl}-2-
	· CH <sub>3</sub> OH	methyl-phenoxy)-acetic
	i G	acid
59	0 0	(4-{2-[(3'-Fluoro
	S N S CH3	biphenyl-4-sulfonyl)
		propyl-amino]
		ethylsulfanyl}-2
	CH <sub>3</sub> OH	methyl-phenoxy) acetic
<u> </u>		acid
60	O CH <sub>3</sub>	(4 {2-{(2' Chloro-
		biphenyl 4 sulfonyl)
		propyl-amino]
	CH. OH	propyl-amino]- ethylsulfanyl}-2-
	CH <sub>3</sub> OH	propyl-amino]
61	,	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid
61	CH <sub>3</sub> OH OH CH <sub>3</sub> CH <sub>3</sub>	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid (4-{2-{(4'-Methoxy-biphenyl-4-sulfonyl)-
61	,	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid (4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino]-
61	O S CH <sub>3</sub>	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2-
61	,	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-{(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino}- ethylsulfanyl}-2- methyl-phenoxy)-acetic
	CI CH <sub>3</sub> CH <sub>3</sub>	propyl amino]- ethylsulfanyl}-2- methyl-phenoxy) acetic acid (4-{2-{(4' Methoxy- biphenyl-4-sulfonyl)- propyl-amino}- ethylsulfanyl}-2- methyl-phenoxy) acetic acid
61	O S CH <sub>3</sub>	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-{(4' Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-{(4' Methoxy-
	CI CH <sub>3</sub> OH	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)-
	CI CH <sub>3</sub> CH <sub>3</sub> OH	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-{(4' Methoxy- biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-{(4' Methoxy-
	CI CH <sub>3</sub> OH	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino]-
62	CI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> OH	propyl amino] ethylsulfanyl}-2- methyl-phenoxy) acetic acid  (4-{2-{(4' Methoxy- biphenyl-4-sulfonyl)- propyl-amino] ethylsulfanyl}-2- methyl-phenoxy) acetic acid  (4-{2-{(4' Methoxy- biphenyl-4-sulfonyl)- propyl-amino] ethylsulfanyl}-2- methyl-phenoxy) acetic acid
	CI CH <sub>3</sub>	propyl amino] ethylsulfanyl}-2- methyl-phenoxy) acetic acid  (4-{2-[(4' Methoxy- biphenyl-4-sulfonyl)- propyl-amino] ethylsulfanyl}-2- methyl-phenoxy) acetic acid  (4-{2-[(4' Methoxy- biphenyl-1-sulfonyl)- propyl-amino] ethylsulfanyl}-2- methyl-phenoxy) acetic acid  (4-{2-[(3'-Chloro-4'-
62	CI CH <sub>3</sub> CH <sub>3</sub> OH	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy) acetic acid  (4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy) acetic acid  (4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy) acetic acid  (4-{2-[(3'-Chloro-4'-fluoro-biphenyl-4-
62	CI CH <sub>3</sub>	propyl-amino] ethylsulfanyl}-2- methyl-phenoxy) acetic acid (4-{2-{(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino] ethylsulfanyl}-2- methyl-phenoxy) acetic acid (4-{2-{(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino] ethylsulfanyl}-2- methyl-phenoxy) acetic acid (4-{2-{(3'-Chloro-4'-fluoro-biphenyl-4-sulfonyl)-propyl-
62	CI CH <sub>3</sub>	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid  (4-{2-[(3'-Chloro-4'- fluoro-biphenyl-4- sulfonyl)-propyl- amino]-ethylsulfanyl}-
62	CI CH <sub>3</sub>	propyl-amino] ethylsulfanyl}-2- methyl-phenoxy) acetic acid (4-{2-{(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino] ethylsulfanyl}-2- methyl-phenoxy) acetic acid (4-{2-{(4'-Methoxy-biphenyl-4-sulfonyl)- propyl-amino] ethylsulfanyl}-2- methyl-phenoxy) acetic acid (4-{2-{(3'-Chloro-4'-fluoro-biphenyl-4-sulfonyl)-propyl-

64	F _ O	(1 (2 f(1 Chlana 2
0-4	F O S CH <sub>3</sub>	(4-{2-{(4-Chloro-3-trifluoromethyl-
	F Y Y O N	benzenesulfonyl)-
		propyl-amino]
		ethylsulfanyl}-2-
	CH <sub>3</sub> OH	
		methyl-phenoxy)-acetic
65	O chiral	(2 Methyl-4-{1-methyl-
05	l 0\li	2 [propyl (4
	F S N S CH <sub>3</sub>	trifluoromethoxy-
	CH, CH,	benzenesulfonyl)-
	F   F   O   O   O   O   O   O   O   O	amino] ethylsulfanyl)
	ĊH₃ OH	phenoxy)-acetic acid
66	O chiral	(2-Methyl-4-(1-methyl-
	O Chinai	2 [propyl (4 propyl
	N Y O Y O Y O Y O Y O Y O Y O Y O Y O Y	benzenesulfonyl)
	CH,	amino]-ethylsulfanyl}-
	H <sub>3</sub> C OH	phenoxy) acetic acid
67	-L:1	(4-{2-[(4-Chloro-3-
07	l LE OLII	trifluoromethyl-
	S S CH <sub>3</sub>	benzenesulfonyl)
	CH <sub>3</sub>	propyl-amino]-1-
	CI CI	methyl-ethylsulfanyl)
	сн₃ о́н	2-methyl-phenoxy)
		acetic-acid
68	chiral	(4-{2-[(3-Chloro-4-
1		
	0	trifluoromethyl-
	CI S N S CH <sub>3</sub>	
	CI S N S CH3	trifluoromethyl-
	F CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)-
	CI S N S CH3	trifluoromethyl- benzenesulfonyl)- propyl-amino] 1-
	F CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl}-
69	F CH <sub>3</sub> OH	trifluoromethyl- benzenesulfonyl)- propyl-amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)-
69	F CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl}- 2-methyl-phenoxy)- acetic acid (4-{2-((4-Butyl- benzenesulfonyl)-
69	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl-amino] 1- methyl-ethylsulfanyl}- 2-methyl-phenoxy)- acetic acid (4-{2-[(4-Butyl-
69	CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl-amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)- acetic acid (4-{2-[(4-Butyl- benzenesulfonyl)- propyl-amino]- ethylsulfanyl} 2-
69	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl-amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)- acetic acid (4-{2-[(4-Butyl- benzenesulfonyl)- propyl-amino]- ethylsulfanyl)-2- methyl-phenoxy)-acetic
	CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl}- 2-methyl-phenoxy)- acetic acid (4-{2-[(4-Butyl- benzenesulfonyl)- propyl amino]- ethylsulfanyl]-2- methyl-phenoxy)-acetic acid
6 <del>9</del>	F CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)- acetic acid (4-{2-[(4-Butyl- benzenesulfonyl)- propyl amino]- ethylsulfanyl] 2- methyl-phenoxy) acetic acid (4-{2-[(4-Isobutyl-
	CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)- acetic acid (4-{2-[(4-Butyl- benzenesulfonyl)- propyl amino]- ethylsulfanyl) 2- methyl-phenoxy) acetic acid (4-{2-[(4-Isobutyl- benzenesulfonyl)-
	CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)- acetic acid  (4-{2-[(4-Butyl- benzenesulfonyl)- propyl amino]- ethylsulfanyl} 2- methyl-phenoxy)-acetic acid  (4-{2-[(4-Isobutyl- benzenesulfonyl)- propyl-amino]-
	CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)- acetic acid (4-{2-[(4-Butyl- benzenesulfonyl)- propyl amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid (4-{2-[(4-Isobutyl- benzenesulfonyl)- propyl-amino]- ethylsulfanyl}-2-
	CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl}- 2-methyl-phenoxy)- acetic acid (4-{2-[(4-Butyl- benzenesulfonyl)- propyl amino]- ethylsulfanyl]-2- methyl-phenoxy)-acetic acid (4-{2-[(4-Isobutyl- benzenesulfonyl)- propyl-amino]- ethylsulfanyl]-2- methyl-phenoxy)-acetic
70	CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)- acetic acid (4-{2-[(4-Butyl- benzenesulfonyl)- propyl amino]- ethylsulfanyl] 2- methyl-phenoxy) acetic acid (4-{2-[(4-Isobutyl- benzenesulfonyl)- propyl amino]- ethylsulfanyl) 2- methyl-phenoxy) acetic acid
	CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)- acetic acid (4-{2-[(4-Butyl- benzenesulfonyl)- propyl amino]- ethylsulfanyl) 2- methyl-phenoxy) acetic acid (4-{2-[(4-Isobutyl- benzenesulfonyl)- propyl-amino]- ethylsulfanyl) 2- methyl-phenoxy) acetic acid (4-{2-[(2-Chloro-4-
70	CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)- acetic acid  (4-{2-[(4-Butyl- benzenesulfonyl)- propyl amino]- ethylsulfanyl} 2- methyl-phenoxy)-acetic acid  (4-{2-[(4-Isobutyl- benzenesulfonyl)- propyl-amino]- ethylsulfanyl) 2- methyl-phenoxy)-acetic acid  (4-{2-[(2-Chloro-4- trifluoromethyl-
70	CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)- acetic acid  (4-{2-[(4-Butyl- benzenesulfonyl)- propyl amino]- ethylsulfanyl] 2- methyl-phenoxy)-acetic acid  (4-{2-[(4-Isobutyl- benzenesulfonyl)- propyl-amino]- ethylsulfanyl) 2- methyl-phenoxy)-acetic acid  (4-{2-[(2-Chloro-4- trifluoromethyl- benzenesulfonyl)-
70	CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)- acetic acid (4-{2-[(4-Butyl-benzenesulfonyl)- propyl amino]- ethylsulfanyl)-2- methyl-phenoxy)-acetic acid (4-{2-[(4-Isobutyl-benzenesulfonyl)- propyl-amino]- ethylsulfanyl)-2- methyl-phenoxy)-acetic acid (4-{2-[(2-Chloro-4- trifluoromethyl- benzenesulfonyl)- propyl-amino]-1-
70	CH <sub>3</sub>	trifluoromethyl- benzenesulfonyl)- propyl amino] 1- methyl-ethylsulfanyl)- 2-methyl-phenoxy)- acetic acid  (4-{2-[(4-Butyl- benzenesulfonyl)- propyl amino]- ethylsulfanyl] 2- methyl-phenoxy)-acetic acid  (4-{2-[(4-Isobutyl- benzenesulfonyl)- propyl-amino]- ethylsulfanyl) 2- methyl-phenoxy)-acetic acid  (4-{2-[(2-Chloro-4- trifluoromethyl- benzenesulfonyl)-

		2 methyl phenoxy)
		acetic acid
<del>72</del>	O chiral	(4-{2-[(4-Bromo-3-
	CI S CH <sub>3</sub>	<del>chloro</del>
		<del>benzenesulfonyl)</del>
	Br CH <sub>3</sub>	propyl-amino]-1-
	CH <sub>3</sub> OH	methyl-ethylsulfanyl}-
	O113	2-methyl-phenoxy)
		acetic acid
73	O chiral	(4 {2 [(4 Butyl 3
	O Chiral	<del>chloro-</del>
		benzenesulfonyl)-
	H <sub>3</sub> C CH <sub>3</sub> CH <sub>3</sub>	propyl-amino] 1
	l сн, он	methyl-ethylsulfanyl}-
	·	2 methyl phenoxy)
		acetic acid
74	Q chiral	(1 {2 [(3 Chloro 4
	CI OSII OS OCH,	isobutyl-
	CH3 TY N TY	benzenesulfonyl)-
	H <sub>3</sub> C CH <sub>3</sub> CO	propyl-amino]-l-
	³ · Сн₃ Он	methyl-ethylsulfanyl}-
	,	2 methyl-phenoxy)
		acetic acid
75	O chiral	(4-{2-{(4-Bromo-
'	O chiral O II S CH <sub>3</sub>	benzenesulfonyl)-
	N TO NOT SOLVE	propyl-amino]-1-
	CH <sub>3</sub>	methyl-ethylsulfanyl}-
	Br	2 methyl-phenoxy)
	Ċн <sub>з</sub> Óн	acetic acid
76	O chiral	(4-{2-[(4-Butyl-
, ,	O Chiral	benzenesulfonyl)
		propyl-amino]-1-
·	H <sub>3</sub> C CH <sub>3</sub> CO	methyl-ethylsulfanyl}-
	CH <sub>3</sub> OH	2-methyl-phenoxy)
İ	3	acetic acid
77	chiral	(4 {2 [(2 Chloro 4'
77	) \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	fluoro-biphenyl-4
	CI S CH <sub>3</sub>	sulfonyl) propyl-
	CH <sub>3</sub>	amino]-1-methyl-
		ethylsulfanyl}-2-
	F CH₃ OH	
		methyl-phenoxy) acetic
70	O chiral	acid
<del>78</del>	م ۱۱	(4-{2-{(3-Chloro-4-
	CI N S CH3	propyl-
	CH <sub>3</sub>	benzenesulfonyl)
	H³C, A A L	propyl-amino]  -
	ĊH <sub>3</sub> ÓH	methyl-ethylsulfanyl}
		2-methyl-phenoxy)
L		acetic acid

0 ' 1	3.1	10/5/0570
Serial	NO.	10/542579

79	,CH₃	(4-{2-[(5-Chloro-3-
		methyl-
	CI CH <sub>3</sub> S OH	benzo[b]thiophene-2-
		sulfonyl)-propyl-
	s ö	amino]-ethylsulfanyl}-
	CH <sub>3</sub>	2-propyl-phenoxy)-
	51.3	acetic acid
80	CH <sub>3</sub>	(4-{2-[(5-Chloro-3-
		methyl-
	OH S	benzo[b]thiophene-2-
1		sulfonyl)-propyl-
	<u> </u>	amino]-ethylsulfanyl}-
	ĊH₃	phenoxy)-acetic acid
81	F_F_	(4-{2-[(5-Chloro-3-
1	F	methyl-
	сн, s—(¬)-о о	benzo[b]thiophene-2-
	CI OH OH	sulfonyl)-propyl-
	s	amino]-ethylsulfanyl}-
	<u> </u>	2-trifluoromethyl-
	CH <sub>3</sub>	phenoxy)-acetic acid
<del>82</del>	F.F.	[2 Methyl 4 (1
	CH <sub>3</sub> CH <sub>3</sub> O	<del>{{propyl (1</del>
	CH, CH	trifluoromethoxy-
		<del>benzenesulfonyl)</del>
	00	amino  methyl}
		<del>propylsulfanyl)-</del>
		phenoxy]-acetic acid
83	CH <sub>3</sub>	(4-{2-[(5-Chloro-3-
	СН <sub>3</sub> S—()—О О	methyl-
		benzo[b]thiophene-2-
		sulfonyl)-propyl-
		amino]-1-methyl-
	CH <sub>3</sub>	ethylsulfanyl}-2-
	, and the second	methyl-phenoxy)-acetic
84	CH <sub>3</sub>	acid (4-{2-[(5-Chloro-3-
04		
	CH <sub>3</sub> O O O O O O O O O O O O O O O O O O O	methyl- benzo[b]thiophene-2-
		sulfonyl)-propyl-
	S-N CH <sub>3</sub> OH	amino]-1-methyl-
	~ ~ ~ /	ethylsulfanyl}-2-
	CH <sub>3</sub>	methyl-phenoxy)-acetic
	-	acid
85	F CH <sub>3</sub> CH <sub>3</sub>	(2-Methyl-4-{2-[(3-
"	F Ch3	methyl-5-
1	「 【 】 Si-N CH₃	trifluoromethyl-
	s ö 🦴	benzo[b]thiophene-2-
	s-<>-0o	sulfonyl)-propyl-
I	1	
	, он	amino]-ethylsulfanyl}-

86	F O CH <sub>3</sub> F O CH <sub>3</sub> F O O O O O O O O O O O O O O O O O O O	(2-Methyl-1-{2-[propyl-(4-trifluoromethyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
87	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> OH	(4-{2-[(4-Ethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy) acetic acid
88	CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	(2-Methyl-4-{2-[(2-methyl-4-trifluoromethoxy-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy) acetic acid
89	FF F O O O O O O O O O O O O O O O O O	(2-Methyl-4-{2-[propyl- (4-trifluoromethoxy- benzenesulfonyl)- amino] ethylsulfanyl}- phenoxy) acetic-acid
90	CH <sub>3</sub> OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
91	CH <sub>3</sub> OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-(3-methyl-butyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

Serial No.: 10/542579

92	CH <sub>3</sub>	(4-{2-[(5-Chloro-3-
	CH <sub>3</sub> S-\langle \rightarrow O	methyl- benzo[b]thiophene-2-
	CI OH OH	sulfonyl)-cyclopropyl-
	S II	amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
93	CH <sub>3</sub> ·	(4-{2-[(5-Chloro-3-
	, сн₃ , s— С , о	methyl-
		benzo[b]thiophene-2- sulfonyl)-cyclobutyl-
	U S-N OH	amino]-ethylsulfanyl}-
	~ ° ° . [7	2-methyl-phenoxy)-
	7	acetic acid
94	,СН <sub>3</sub>	(4-{2-[(5-Chloro-3-
	ÇH₃ S————O O	methyl-
		benzo[b]thiophene-2-
	; N ОН	sulfonyl)-
	° s ö ✓	cyclopropylmethyl- amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
95	<sub>_</sub> CH₃	(4-{2-[(5-Chloro-3-
	çн₃ s—(¯)—о о	methyl-
		benzo[b]thiophene-2-
	OH OH	sulfonyl)-pentyl-amino]-   ethylsulfanyl}-2-
	\ \ \	methyl-phenoxy)-acetic
		acid
	,CH³	
96	CH <sub>3</sub>	(4-{2-[Butyl-(5-chloro-
	çн₃ s—⟨¯⟩—о о	3-methyl-
		benzo[b]thiophene-2-   sulfonyl)-amino]-
	S S O	ethylsulfanyl}-2-
ļ ,	<b>~</b> <	methyl-phenoxy)-acetic
	H³C	acid
97	_ CH <sub>3</sub>	(4-{2-{(Biphenyl-4-
/		sulfonyl) propyl
	S-N CH3	amino] ethylsulfanyl}
	s—( )—o, o	2-methyl-phenoxy)-
		acetic acid
98	CH₃	(4-{2-[(5-Chloro-3-
70		methyl-
	CI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	benzo[b]thiophene-2-
		sulfonyl)-propyl-
	<sup>™</sup> s ö ⟩	amino]-ethoxy}-2-
	CH <sub>3</sub>	methyl-phenylsulfanyl)-

		acetic acid
99	,СН <sub>3</sub>	(4-{3-[(5-Chloro-3-
	·	methyl-
	CI <sub>2</sub> CH <sub>3</sub> CH <sub>3</sub>	benzo[b]thiophene-2-
•	S-N OH	sulfonyl)-propyl-
	s´ ő `	amino]-propyl}-2-
ł	\	methyl-phenoxy)-acetic
	CH <sub>3</sub>	acid
100	,CH₃	(4-{2-[(5-Chloro-3-
	<i>/</i> =<	methyl-
	CH <sub>3</sub> O-( )-O O	benzo[b]thiophene-2-
İ	S-N CH. OH	sulfonyl)-propyl-
	S OH	amino]-1-methyl-
	~	ethoxy}-2-methyl-
	,CH³	phenoxy)-acetic acid
101	CH <sub>3</sub>	3-(4-{2-[(5-Chloro-3-
'''	/=<\\^3	methyl-
	CH <sub>3</sub> O— O	benzo[b]thiophene-2-
		sulfonyl)-propyl-
	CI CH <sub>3</sub> O CH <sub>3</sub> OH	amino]-1-methyl-
	~ 3 0 /	ethoxy}-2-methyl-
	Сн <sub>з</sub>	phenyl)-propionic acid
102	CH <sub>3</sub>	2-(4-{2-[(5-Chloro-3-
102		methyl-
	, cH₃ o-⟨ }-o o	benzo[b]thiophene-2-
	CI S N CH <sub>3</sub> H <sub>3</sub> C OH	sulfonyl)-propyl-
	S S OH	amino]-1-methyl-
		ethoxy}-2-methyl-
Í	CH <sub>3</sub>	phenoxy)-2-methyl-
		propionic acid
103	O-CH <sub>3</sub>	3-(4-{2-[(5-Chloro-3-
[	/ •	methyl-
	CI CH <sub>3</sub> O CH	benzo[b]thiophene-2-
	S-N CH <sub>3</sub> OH	sulfonyl)-propyl-
	s´s´b`	amino]-1-methyl-
	\ 	ethoxy}-2-methoxy-
	, СН <sup>3</sup>	phenyl)-propionic acid
104	<sub>_</sub> CH₃	(4-{2-[(5-Fluoro-3-
	CH, S——O O	methyl-
	F	benzo[b]thiophene-2-
	F CH <sub>3</sub> S O O O O O O O O O O O O O O O O O O	sulfonyl)-propyl-
	s ö >	amino]-1-methyl-
	( CH	ethylsulfanyl}-2-
	CH <sub>3</sub>	methyl-phenoxy)-acetic
		acid

105	CH <sub>3</sub>	3-(4-{2-[(5-Fluoro-3-
	F S O CH <sub>3</sub> OH	methyl-
	F	benzo[b]thiophene-2-
	[ [ ] —ÿ-n( `cн₃ `oн	sulfonyl)-propyl-
	S Ö ⟩	amino]-1-methyl-
	CH <sub>3</sub>	ethoxy}-2-methyl-
106	CH <sub>3</sub>	phenyl)-propionic acid
100	/ <del>=</del> <	(4-{2-[(5-Fluoro-3- methyl-
	CH3 O— DO O	benzo[b]thiophene-2-
	S CH <sub>3</sub> OH	sulfonyl)-propyl-
	s	amino]-1-methyl-
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	ethoxy}-2-methyl-
	CH <sub>3</sub>	phenoxy)-acetic acid
107	,CI	(2-Chloro-4-{2-[(5-
	CH₃ S——O O	chloro-3-methyl-
		benzo[b]thiophene-2-
	CI OH OH	sulfonyl)-propyl-
	S S S	amino]-ethylsulfanyl}-
	CH <sub>3</sub>	phenoxy)-acetic acid
108	CI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub>	(4-{2-[(5-Chloro-3-
100	CI CI	methyl-
	S-S-N CH <sub>3</sub>	benzo[b]thiophene-2-
		sulfonyl)-propyl-
		amino]-ethylsulfanyl}-
	, ОН	2-ethyl-phenoxy)-acetic
100		acid
109	OH	(2-Methyl-4-{2-
	O=_O, CH <sub>3</sub>	[(naphthalene-2
	CH <sub>3</sub>	sulfonyl) propyl- amino] ethylsulfanyl}
		phenoxy) acetic acid
	S	phonony) doctro dold
	o.s.	
	<u> </u>	
110		(4-{2-{(5-Fluoro-3-
110	0 S	<del>(4 (2 ((3 Filloro 3</del>
	H <sub>3</sub> C	benzo[b]thiophene-2-
	H₃C O S F F O CH.	sulfonyl)-propyl-
	H <sub>3</sub> C	amino]-ethylsulfanyl}-
	HO \$	2-methyl-phenoxy)
		acetic acid
	0	

111	CII	[ f2 Ol 1
111	CH <sub>3</sub> CH <sub>3</sub>	(3-Chloro-4-(1-
		<del>{[propyl-(4-</del>
	F-O-( )-S-N-/S-( )-	trifluoromethoxy-
	F DH	benzenesulfonyl)-
	CI O	amino]-methyl}-
		propylsulfanyl)-phenyl]-
		acetic acid
112	CH <sub>3</sub> Chiral	(R)-(3-Chloro-4-{2-[(5-
		chloro-3-methyl-
	S SHO CHCI O OH	benzo[b]thiophene-2-
	V 15 OH ) 311321 0	sulfonyl)-propyl-
	CH,	amino]-1-methyl-
		ethylsulfanyl}-phenyl)-
		acetic acid
113	(T)	(3-Chloro-4-{2-[(5-
'''	CI CH S HO	chloro-3-methyl-
		benzo[b]thiophene-2-
	j > s - n Cı HO	sulfonyl)-propyl-
	✓∕s ö	
	CH₃	amino]-ethylsulfanyl}- phenyl)-acetic acid
114	F	• • • · · · · · · · · · · · · · · · · ·
114	`	[4-(1-{[(5-Fluoro-3-
	CH, CH, O	methyl-
		benzo[b]thiophene-2-
	S S N O OH	sulfonyl)-propyl-
	O's'N' O	amino]-methyl}-
		propoxy)-2-methyl-
	\ H³C, CH³	phenoxy]-acetic acid
115	F	2 [4 (1 ([/5 E]) 2
115		3-[4-(1-{[(5-Fluoro-3-
	CH CH <sub>3</sub> O	methyl-
	CH <sub>3</sub>	benzo[b]thiophene-2-
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	sulfonyl)-propyl-
	o s s s s s s s s s s s s s s s s s s s	amino]-methyl}-
		propoxy)-2-methyl-
	CH3c	phenyl]-propionic acid
116	CI	3-(4-{2-[(5-Chloro-3-
	ÇH₃ Ç	methyl-
	CH <sub>3</sub> CH <sub>3</sub> OH	benzo[b]thiophene-2-
	ا ال الكاكسية ا	sulfonyl)-propyl-
	s s s	amino]-butoxy}-2-
		methyl-phenyl)-
	<u> </u>	propionic acid
Ĺ	ĊH₃	

117	CH <sub>3</sub> CH <sub>3</sub> O OH	.[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-acetic acid
118	CI CH <sub>3</sub> O OH S.C. CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> OOH CH <sub>3</sub> O	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methoxy-phenoxy]-acetic acid
119	CH <sub>3</sub> O O O O O O O O O O O O O O O O O O O	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-phenethyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
120	CI CH <sub>3</sub> OO OO OO OO OO OO OO OO OO OO OO OO OO	(4-{2-[Benzyl-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid: and
121	CH <sub>3</sub> OOH OH	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid

25. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound of Claim 1 or pharmaceutically acceptable salts, solvates or hydrates thereof.

- 26. (Cancelled)
- 27. (Cancelled)

- 28. (Cancelled)
- 29. (Cancelled)
- 30. (Cancelled)
- 31. (Cancelled)
- 32. (Cancelled)
- 33. (Cancelled)
- 34. (Previously Presented) A method for lowering blood-glucose in a mammal comprising the step of administering an effective amount of at least one compound of Claim 1.
  - 35. (Cancelled)
  - 36. (Cancelled)
  - 37. (Cancelled)
  - 38. (Cancelled)
  - 39. (Cancelled)
  - 40. (Cancelled)